cardiac hypertrophy, namely protein synthesis, NFAT and MAP kinase signaling. Hence, this study was undertaken to identify a novel mechanism by which AMPK can regulate cardiac hypertrophy.
Results: First, we showed that PE-dependent cardiomyocyte hypertrophy was accompanied by an increase in O-GlcNAc levels. This hypertrophy was prevented by A769662 and this was associated with a decrease in O-GlcNAc levels. Then, using hexosamine biosynthesis pathway activators, i. e PUGNAc or glucosamine, we showed that increase in O-GlcNAc levels was able to reverse the anti-hypertrophic effect of AMPK activation in NRVMs. Similar results were obtained in adult rat cardiomyocytes. On the other hand, inhibition of hexosamine biosynthesis pathway by Azaserine or DON inhibited PE-induced cardiomyocyte hypertrophy and this effect was reversed by PUGNAc or glucosamine. In vivo experiments confirmed these in vitro data. Indeed, metformin was able to reduce cardiac hypertrophy and this correlated with a decrease in O-GlcNAc levels in WT mice but not in AMPKα2 knockout mice.
Conclusion:
Collectively, our results suggest that AMPK regulates cardiac hypertrophy mainly by inhibiting O-GlcNAcylation signaling. AMPK and OGlcNAcylation signaling could be putative new therapeutic targets for treatment of cardiac hypertrophy.
Endothelium dependent relaxation and T-type voltage-gated calcium channels
Guillaume Gilbert, Arnaud Courtois, Thomas Ducret, Jean-Pierre Savineau, Jean-François Quignard Université de Bordeaux, CRCTB INSERM U1045, Bordeaux, France T-type voltage-gated calcium channels (T-VGCC) are involved in the regulation of pulmonary arterial tone. Besides their roles in smooth muscle cell contraction, we investigate if T-VGCC could control vascular relaxation via endothelial calcium signaling regulation in mouse pulmonary arteries. Immunofluorescence labeling indicates that endothelial cells (as well as smooth muscle cells) express T-VGCC proteins (Cav3.1 and Cav3.2 isotypes). We show that nitric oxide (NO)-dependent relaxation induced by acetylcholine is reduced in the presence of T-VGCC antagonists (mibefradil, NNC 55-0396) and in Cav3.1 knock-out mice. Acetylcholine induces an endothelial intracellular calcium increase which is reduced by the same types of inhibitors. By contrast, endothelium dependent relaxation induced by beta 2 adrenergic stimulation (with procaterol), which is calcium independent, is not inhibited by mibefradil or in Cav3.1 knock-out mice. Furthermore, in pathological condition (pulmonary hypertension induced by a chronic hypoxia), acetylcholine-mediated relaxation is reduced and even more in Cav3.1 knockout mice. In summary, in mice pulmonary arteries, acetylcholine and calciumdependent dilatation require T-VGCC. The present findings suggest that calcium influx through T-VGCC mediate a dual effect in pulmonary artery: a contraction when it occurred in smooth muscle cells and a dilatation when it occurred in endothelial cells.
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Smooth muscle specific Rac1 deficiency induces hypertension by over activation of RhoA/Rho-kinase signaling pathway Gwennan André, Gervaise Loirand, Vincent Sauzeau Institut du Thorax, INSERM U1087, Nantes, France
The small GTPase RhoA and its target, Rho kinase, play essential role in both blood pressure regulation and vascular smooth muscle contraction. Increasing evidence implicates over activation of this signaling pathway as a critical event in the pathogenesis of hypertension. Interestingly, it has been recently described that Rac1 could antagonize RhoA-dependent functions. However, the role of Rac1 in the regulation of vascular tone and blood pressure is not fully elucidated. Here we assessed the hypothesis that smooth muscle Rac1 participates in the control of blood pressure. To define the role of vascular smooth muscle cells (vSMC) Rac1 in vivo in the control of blood pressure, we generated inducible, smooth muscle (SM)-specific Rac1 knockout mice (SM-Rac1-KO) and analyzed cardiovascular parameters. Following induction of Rac1 deletion, SM-Rac1-KO mice rapidly develop high systolic blood pressure (+15±2 mmHg, n=19, p=0.02). Treatment with the Rho kinase inhibitor fasudil decreases systolic arterial pressure to a level similar in control and SM-Rac1-KO mice suggesting that RhoA/Rho kinase signaling is involved in the rise in systolic blood pressure induced by SM-Rac1 deletion. This is confirmed by immunoblot analysis in aorta that reveals an increase of activated RhoA (348± 19% of control, n=4, p<0.05) and Rho-kinase activity (390±25% of control, n=4, p<0.05) in SM-Rac1-KO compared to control mice. This overactivation of RhoA signaling in SM-Rac1-KO mice is associated with a 75%-reduction of the inhibitory phosphorylation of RhoA on Ser188 compared to control mice. At functional level, while NO production is not modified, NO-dependent vasodilation is decreased in SM-Rac1-KO arteries (≈ 56% of control). By in vitro experiments in vSMC, we demonstrate that the loss of Rac1 leads to a defective production of cGMP and a down-regulation of the cGMP-dependent kinase-mediated inhibition of RhoA/Rho kinase signaling. These results thus identified a blood pressurelowering effect of vSMC Rac1, that tonically antagonizes RhoA/Rho kinase activity to modulate arterial tone and blood pressure through cGMP/ cGMP-dependent kinase pathway.
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The activation function-1 (AF1) of estrogen receptor α prevents arterial neointima through a direct effect on smooth muscle cells Natalia Smirnova (1), Coralie Fontaine (2), Mélissa Buscato (1), Alexia Vinel (1), Adrien Lupieri (1), Jean-Michel Foidart (3), John A. Katzenellenbogen (4), Pierre Gourdy (2), Françoise Lenfant (1) Estradiol (E2) regulates gene transcription through nuclear Estrogen Receptor alpha (ERα) thanks to two Activation Functions, AF-1 and AF-2, but can activate membrane ERα and thereby rapid « non genomic » signals. Some tissue-specific stimulatory roles of these ERα functions have already been described: for instance ERαAF1 and membrane ERα activation are each necessary and sufficient to induce endometrial epithelial proliferation and to accelerate endothelial healing respectively in response to E2.
E2 can also inhibit vascular smooth muscle cell proliferation, but the mechanisms of this action are poorly recognized. Using a mouse model of femoral artery injury, we found that 1) E2 prevents intimal smooth muscle hyperplasia. 2) Selective inactivation of ERα in smooth muscle cells abrogates this protective action, whereas its endothelial and hematopoietic inactivation did not alter this effect. 3) Estrogen dendrimer conjugate, a selective activator of membrane ERa, fail to prevent intimal hyperplasia. 4) E2 does not inhibit post-injury arterial smooth muscle cell proliferation in mice selectively deficient in ERαAF1 (through deletion of the N-terminal A/B domain which harbors this function), demonstrating that ERαAF1 is necessary to mediate this effect, 5) Finally, tamoxifen, a selective partial AF-1 activator of ERα, is sufficient to prevent the hyperplasia. Altogether, we demonstrate here, for the first time, that ERαAF1 activation is both necessary and sufficient to prevent post-injury arterial smooth muscle cell proliferation, in striking contrast to its stimulatory action on the endometrial epithelium. This underlines the exquisite tissue-specific actions of ERα subfunctions as well as of selective ER modulators, and shed some light on one of the most intriguing mysteries of biology of estrogens.
